Ocular measures for detection of driving impairment due to sleep loss, alcohol and benzodiazepine use
Austin Health
32 participants
Apr 1, 2009
Interventional
Conditions
Summary
This study will examine whether the impairing effects of sleep loss, alcohol and hypnotic drugs can be detected using a simulated driving task and drowsiness monitoring technology in the laboratory setting. The hypothesis of this study is that performance deterioration, as a result of sleep restriction and acute benzodiazepine administration, can be detected by increases in slow eyelid closure, a reduction in amplitude of eyelid opening and a reduction in saccadic eye movements, as measured by Optalert.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All participants will undergo three randomised sessions, seperated by a 1 week washout period. 1. Sleep restriction session: sleep will be restricted to 4 hours on the night prior to testing (2am to 6am). 2. benzodiazepine session: a single, 20mg oral dose of benzodiazepine administered at 9am, 2 hours prior to testing 3. alcohol session: measured doses of vodka in orange juice will be administrered orally until a blood alcohol concentration (BAC) of 0.05% and 0.08% is reached (checked by alcometer). Testing will commence immediately at each alcohol level. During testing, driving simulation and a reaction time task will be completed, while ocular parameters are measured, using optalert and electrooculography (EOG).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000289213